Medical Condition News

RSS

Head and neck cancer survivors who smoke and drink face increased risk of death

Cigarette smoking and alcohol consumption before head and neck cancer diagnosis strongly predicts the patient's future risk of death, according to published studies. Now, results of a new study show a similar effect among those who continued these habits after cancer diagnosis.

3 Dec 2009

CT imaging after chemotherapy with bevacizumab may help predict overall survival

Preliminary research suggests that criteria based on computed tomography (CT) imaging of changes in tumors from colorectal liver metastases after chemotherapy with the drug bevacizumab may have the potential to predict overall survival, according to a study in the December 2 issue of JAMA.

3 Dec 2009

New study links cigarette smoking with colorectal cancer

New study results strengthen the evidence that people who smoke cigarettes over a long period of time have an increased risk for developing colorectal cancer, even after adjusting for other risk factors.

3 Dec 2009

Manpei Suzuki Diabetes Foundation announces the 2009 winner of International Prize

The Manpei Suzuki Diabetes Foundation is pleased to announce the 2009 winner of the International Prize: Donald F. Steiner, MD, A. N. Pritzker Distinguished Service Professor Emeritus, Departments of Medicine and Biochemistry and Molecular Biology, The University of Chicago, USA.

3 Dec 2009

People who smoke immediately after waking up face high risk of lung cancer

People who smoke their first cigarette within minutes after waking up have much higher levels of cotinine, a by-product of nicotine when processed by the body, than those who wait to smoke, regardless of the number of cigarettes smoked.

3 Dec 2009

Huntington Memorial Hospital's stroke program receives Gold Seal of Approval

Huntington Memorial Hospital's stroke program has received the Gold Seal of Approval from the Joint Commission, designating the hospital a primary stroke center. This means Huntington will join the network of "approved stroke center" hospitals throughout Los Angeles County.

3 Dec 2009

FDA grants Fast Track designation for Keryx Biopharmaceuticals' KRX-0401

Keryx Biopharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, for the treatment of relapsed/refractory multiple myeloma.

3 Dec 2009

Earlier diagnosis of cancer saves 5,000 to 10,000 lives each year, says Professor Mike Richards

Earlier diagnosis of people with cancer could save between 5,000 and 10,000 lives each year, Professor Mike Richards, the National Cancer Director for England, has claimed.

3 Dec 2009

New study reveals smokeless tobacco products contain high levels of cancer-causing substances

A new study on the smokeless tobacco product called moist snuff - placed between lip and gum - has led scientists in Minnesota to urge the tobacco industry to change manufacturing practices to reduce snuff's content of carcinogens.

3 Dec 2009

Exercise remains one of the most effective interventions for peripheral artery disease

Peripheral artery disease (PAD) affects 5 million individuals in the U.S. and is the leading cause of limb amputations. Doctors have long considered exercise to be the single best therapy for PAD, and now a new study helps explain why. Led by researchers at Beth Israel Deaconess Medical Center and published in this week's Online Early Edition of the Proceedings of the National Academy of Sciences (PNAS), the findings demonstrate that a protein called PGC-1alpha plays a key role in the process.

3 Dec 2009

Repeated use of ecstasy drug increases the risk of developing sleep apnea

Repeated use of the drug popularly known as "ecstasy" significantly raises the risk of developing sleep apnea in otherwise healthy young adults with no other known risk factors for the sleep disturbance, a new study by Johns Hopkins scientists suggests.

2 Dec 2009

Kalbitor drug approved by FDA

The U.S. Food and Drug Administration approved Kalbitor (ecallantide) on Dec. 1 to treat sudden and potentially life-threatening fluid buildup that can occur in people with a rare genetic condition known as hereditary angioedema (HAE).

2 Dec 2009

Research finds change in the outlook of people with type 2 diabetes and heart disease

The outlook for individuals with type 2 diabetes and coronary artery disease is not as grim as originally believed, according to new Saint Louis University research published in Circulation, the Journal of the American Heart Association.

2 Dec 2009

Researchers discover ability of stem cells in brain cancer glioma to resist radiation therapy

Duke University Medical Center researchers have figured out how stem cells in the malignant brain cancer glioma may be better able to resist radiation therapy. And using a drug to block a particular signaling pathway in these cancer stem cells, they were able to kill many more glioma cells with radiation in a laboratory experiment.

2 Dec 2009

Adult stem cells may help repair heart tissue, reveals new study

Adult stem cells may help repair heart tissue damaged by heart attack according to the findings of a new study to be published in the December 8 issue of the Journal of the American College of Cardiology. Results from the Phase I study show stem cells from donor bone marrow appear to help heart attack patients recover better by growing new blood vessels to bring more oxygen to the heart.

2 Dec 2009

Study on the genetics of osteoarthritis

Interleukin Genetics, Inc. and NYU Langone Medical Center announced findings from a study performed in collaboration with Duke University on the genetics of osteoarthritis have been published this week in the "Online First" version of the Annals of Rheumatic Diseases and is available at http://ard.bmj.com/cgi/rapidpdf/ard.2009.113043v1.pdf.

2 Dec 2009

Javelin Pharmaceuticals submits an NDA for Dyloject Injection

Javelin Pharmaceuticals, Inc., a leading developer and marketer of specialty pharmaceutical products for pain management, today announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational product candidate, Dyloject™ (diclofenac sodium) Injection, for the management of acute moderate-to-severe pain in adults.

2 Dec 2009

Patient enrollment complete in Peregrine Pharmaceuticals' Cotara trial

Peregrine Pharmaceuticals, Inc. today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with relapsed glioblastoma multiforme (GBM), the deadliest form of brain cancer. Cotara is a targeted monoclonal antibody linked to a radioisotope being developed as a potential new treatment for GBM.

2 Dec 2009

Sorin Group includes the first patient in its Clepsydra clinical trial

Sorin Group announced today the first inclusion of a patient in the Clepsydra clinical trial. The study will investigate the sensitivity to changes in heart failure status of PhD™, a unique diagnostic feature using the dual sensor technology of minute ventilation and accelerometer to monitor patient’s breathing and activity levels every day.

2 Dec 2009

Ellipse Technologies presents clinical results of its MAGEC System study

Ellipse Technologies, Inc. announced today that a scientific presentation of the pre-human clinical results of the MAGEC System were presented by Dr. Gregory Mundis at the 3rd International Congress on Early Onset Scoliosis and Growing Spine held in Istanbul, Turkey, November 20 and 21st.

2 Dec 2009